Droperidol: past, present and future

Sneyd, J. R.

doi:10.1111/j.1365-2044.2009.06124.x

Cited by 13 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…1,2 It was first approved in Denmark in 1963 for use with anesthesia in order to limit postoperative nausea and vomiting (PONV). 2 Since the late 1970s, low-dose droperidol (0.625e1.25 mg) has been widely used to prevent and treat PONV in adults and children. 3,4 The management of postoperative pain with intravenous patient-controlled analgesia (IVPCA) is common in many hospitals due to its rapid and reliable analgesic effect, avoidance of intramuscular injections, and high patient satisfaction.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

To add or not to add? An empirical study on droperidol and intravenous patient-controlled analgesia

Kuo¹,

Tsou²,

Chang³

et al. 2012

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

To add or not to add? An empirical study on droperidol and intravenous patient-controlled analgesia

Kuo¹,

Tsou²,

Chang³

et al. 2012

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

show abstract

“…Overall, side effects are usually mild and are estimated to be experienced by 4% of those who receive them. 21 The side effects of the drug classes are as follows: 5HT 3 receptor antagonists: headache, elevated liver enzymes, constipation, and QTc prolongation in higher doses; 22 corticosteroids: hyperglycemia, shortened duration of rocuronium-induced neuromuscular blockade, perineal pruritus, and bradycardia, [23][24][25][26] the incidence of postoperative wound infections does not appear to increase following the use of dexamethasone; 27 NK-1 receptor antagonists: dizziness, headaches, and constipation; 28,29 butyrophenones: sedation, hypotension, and extrapyramidal symptoms, 22 pathological QTc prolongation does not occur with doses used for PONV prophylaxis; 30 antihistamines: sedation, dry mouth, and constipation; 29,31 anticholinergic agents: dry mouth, drowsiness, and visual disturbances; 32 benzodiazepines: sedation; 33 alpha-2 agonists: hypotension and sedation; phenothiazines: sedation; 34 gabapentin: somnolence and dizziness; 35 PC6 acupoint stimulation: skin irritation, blistering, redness, and pain. 36…”

Section: Pathophysiology Of Ponvmentioning

confidence: 99%

Ambulatory anesthesia and postoperative nausea and vomiting: predicting the probability

Hegarty

Buckley

McCaul

2016

View full text Add to dashboard Cite

Nausea and vomiting are distinctly unpleasant symptoms that may occur after surgery and anesthesia, and high priority is given to their prevention by patients. Research in this area is plentiful and has focused on event prediction and pharmacological prophylaxis but despite this, postoperative nausea and vomiting (PONV) typically occurs in 20%-30% of patients in contemporary practice. Prediction of postoperative and postdischarge nausea and vomiting is particularly important in the ambulatory surgical population as these symptoms may occur following discharge from hospital and continue for up to one week when access to antiemetic therapies is limited. Many of the existing predictive scoring systems are based on data from inpatient populations and limited to the first 24 hours after surgery. Scoring systems based on data from ambulatory surgical populations to predict PONV are only moderately good. The best-performing systems in ambulatory patients are those of Sinclair and Sarin with an area under the receiver operating characteristic curve of 0.78 and 0.74, respectively, but are limited by the short duration of follow-up and a greater emphasis on nausea than vomiting. Given that the ability to predict both PONV and postdischarge nausea and vomiting is clearly limited, emphasis has been placed on prophylactic strategies that incorporate antiemetic medication, intravenous hydration, and nonnarcotic analgesia. PONV has been reduced to <10% in institutions using multimodal approaches. Scoring systems may facilitate "risk tailoring" in which patient risk profile is used as a stratification method for pharmacointervention.

show abstract

“…Recientemente se ha reintroducido con dos únicas indicaciones: prevención y tratamiento de las NVPO, y de las NV inducidas por la morfina o derivados en la analgesia controlada por el paciente (PCA). En otros países es actualmente recomendado como fármaco de primera línea en la profilaxis de NVPO (30).…”

Section: Profilaxis En El Adultounclassified

Recomendaciones de prevención y tratamiento de las náuseas y vómitos postoperatorios y/o asociados a las infusiones de opioides

Gómez-Arnau

Aguilar

Bovaira

et al. 2010

Revista Española de Anestesiología y Reanimación

View full text Add to dashboard Cite

Postoperative nausea and vomiting (PONV) causes patient discomfort, lowers patient satisfaction, and increases care requirements. Opioid-induced nausea and vomiting (OINV) may also occur if opioids are used to treat postoperative pain. These guidelines aim to provide recommendations for the prevention and treatment of both problems. A working group was established in accordance with the charter of the Sociedad Española de Anestesiología y Reanimación. The group undertook the critical appraisal of articles relevant to the management of PONV and OINV in adults and children early and late in the perioperative period. Discussions led to recommendations, summarized as follows: 1) Risk for PONV should be assessed in all patients undergoing surgery; 2 easy-to-use scales are useful for risk assessment: the Apfel scale for adults and the Eberhart scale for children. 2) Measures to reduce baseline risk should be used for adults at moderate or high risk and all children. 3) Pharmacologic prophylaxis with 1 drug is useful for patients at low risk (Apfel or Eberhart 1) who are to receive general anesthesia; patients with higher levels of risk should receive prophylaxis with 2 or more drugs and baseline risk should be reduced (multimodal approach). 4) Dexamethasone, droperidol, and ondansetron (or other setrons) have similar levels of efficacy; drug choice should be made based on individual patient factors. 5) The drug prescribed for treating Este trabajo ha sido financiado mediante la concesión de una subvención de ProStrakan Farmacéutica SL a la Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor.Aceptado para su publicación en agosto de 2010.Rev. Esp. Anestesiol. Reanim. 2010; 57: 508-524. Reproducido con permiso de REDAR.

show abstract

Droperidol: past, present and future

Cited by 13 publications

References 38 publications

To add or not to add? An empirical study on droperidol and intravenous patient-controlled analgesia

To add or not to add? An empirical study on droperidol and intravenous patient-controlled analgesia

Ambulatory anesthesia and postoperative nausea and vomiting: predicting the probability

Recomendaciones de prevención y tratamiento de las náuseas y vómitos postoperatorios y/o asociados a las infusiones de opioides

Contact Info

Product

Resources

About